Pre-Made Ensomafusp Biosimilar, Fusion Protein targeting CD19: Recombinant therapeutic protein targeting B4/CVID3 for drug discovery and mechanism of action (MOA) research

Pre-Made Ensomafusp Biosimilar, Fusion Protein targeting CD19: Recombinant therapeutic protein targeting B4/CVID3 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Anti-CD19 Acute leukemia is considered as the most common form of childhood malignancies. CD19 is a 95- kDa transmembrane glycoprotein which belongs to the immunoglobulin (Ig) superfamily and can act as a central positive response regulator in B cells. The CD19 has been expressed on the surface of leukemia cells in > 90% of cases with acute lymphoblastic leukemia. Moreover, it can be expressed on tumor cells of cases with both B-cell and chronic lymphocytic leukemia. Thus, CD19 antigen is an ideal target for immunotherapy of B-cell malignancies. CD19 can act as a B cell co-receptor in conjunction with both CD21 and CD81. Genetic studies show that CD19 has a role in keeping a balance between immunity and autoimmunity. Although both CD19 and CD22 have their own regulatory network, they do not modulate B cell receptor (BCR) signals independently. Antibody-based therapies targeting CD19 using anti CD19 monoclonal antibodies (mAbs) have lately been used for B-cell acute lymphoblastic leukemia as a promising new therapeutic anticancer drug.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-664-1mg	1mg	3090
GMP-Bios-ab-664-10mg	10mg	Inquiry
GMP-Bios-ab-664-100mg	100mg	Inquiry
GMP-Bios-ab-664-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ensomafusp Biosimilar, Fusion Protein targeting CD19: Recombinant therapeutic protein targeting B4/CVID3
INN Name	Ensomafusp
Target	CD19
Format	Fusion Protein
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2021
Year Recommended	na
Companies	Roche
Conditions Approved	na
Conditions Active	B cell Lymphoma
Conditions Discontinued	na
Development Tech	na